Drug Profile
ONYX 411
Alternative Names: ONYX-411Latest Information Update: 19 Feb 2008
Price :
$50
*
At a glance
- Originator Onyx Pharmaceuticals
- Class Antineoplastics; Oncolytic viruses
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 07 May 2007 Preclinical trials in Solid tumours in USA (IV)
- 07 May 2007 Data presented at the 98th Annual Meeting of the American Association for Cancer Research (AACR-2007) added to the Cancer pharmacodynamics section
- 16 Feb 2006 No development reported - Preclinical for Solid tumours in USA (unspecified route)